Michael Grant, MD
Urology · Lebanon, NHNPI 1578901195
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (39.8%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 6 manufacturers reported payments, led by Neotract Inc. at 47.8% of the total. Reporting peaked in 2021 at $811 and has fallen 59.3% since, to $330 in 2025.
Across 18 payments — averaging $126.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neotract Inc.$1K
- Boston Scientific$846
- Johnson & Johnson$153
- SRS Medical Systems, Inc.$146
- Janssen Scientific Affairs, LLC$30
- Rochester Medical Corporation$11
What the payments were for
- Consulting fees$80035%
- Travel & lodging$90540%
- Food & beverage$57025%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neotract Inc. | 12 | $1,088 |
| Boston Scientific | 2 | $846 |
| Johnson & Johnson | 1 | $153 |
| SRS Medical Systems, Inc. | 1 | $146 |
| Janssen Scientific Affairs, LLC | 1 | $30 |
| Rochester Medical Corporation | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UroLift$875
- REZUM$800
- Erleada$153
- CT3000 Pro Base Unit$146
- UroCuff-DC Disposable, Single$146
How this compares
$2,275 in reported general payments places this provider in the 70th percentile of 61 urology providers in New Hampshire.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 98 | $112,828 |
| GemtesaVibegron | 12 | $15,715 |
| Mirabegron ErMirabegron | 13 | $9,184 |
| Tamsulosin Hcl | 346 | $6,141 |
| Finasteride | 375 | $5,674 |
| Oxybutynin Chloride ErOxybutynin Chloride | 47 | $1,762 |
| Dutasteride | 23 | $1,022 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 36 | $1,007 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 15 | $377 |
| Cephalexin | 33 | $100 |
| Ciprofloxacin Hcl | 16 | $96 |
Paid to pharmacies, not to this prescriber.
Other urology in Lebanon
- Lori LernerLebanon$49K
- Roland ChenLebanon$3K
- Vernon PaisLebanon$2K
- Nicholas MollLebanon$1K
- Rachel MosesLebanon$657
- Elizabeth GormleyLebanon$427
- John SeigneLebanon$331
- David ChavezLebanon$278
- Einar SverrissonLebanon$168
- Ricky PhelpsLebanon$51
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.